Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : buys US firm Kite Pharma for $11.9bn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:14pm CEST

Biopharmaceutical company Gilead Sciences has completed the acquisition of US-based Kite Pharma for approximately $11.9bn.

Kite Pharma specialises in the development of new cell therapies, which use a patients own immune cells to fight cancer.

Gilead Sciences has completed the transaction through Dodgers Merger Sub, a wholly owned subsidiary of the company.

On 28 August, the two companies entered a definitive merger agreement to complete the acquisition.

A tender offer was started on 5 September to buy all the outstanding shares of Kite Pharma at a price of $180 each.

Gilead Sciences has successfully concluded the tender offer for all of Kite Pharma`s common stock shares.

"Kite Pharma has become a wholly owned subsidiary of Gilead Sciences."

Gilead Sciences president and chief executive officer Dr John F Milligan said: Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them."

With the completion of the acquisition, Kite Pharma has become a wholly owned subsidiary of Gilead Sciences.

Bank of America Merrill Lynch, Lazard and Barclays acted as financial advisors to Gilead Sciences, while Skadden, Arps, Slate, Meagher and Flom served as the companys legal advisors.

Kite Pharma has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the form of cancer.

The companys major CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL).

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10:07a GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
04:35a GILEAD SCIENCES : UMass Medical School shares $7.5M HIV grant
10/17 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
10/12 GILEAD SCIENCES : An Application for the Trademark "NASH360" Has Been Filed by G..
10/12 GILEAD SCIENCES : High-Stakes Gilead Case Lands Fish & Richardson Principals Jua..
10/12 GILEAD SCIENCES : Completes Acquisition of Kite Pharma, Inc.
10/12 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/12 GILEAD SCIENCES : Presents Results From Phase 3 Study Evaluating Patients Who Sw..
More news
News from SeekingAlpha
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 GILEAD : My Only 'Buy 'Til You Die' Investment,  A Deep Due Diligence Dive
10/16 Q3 ROUNDUP : Top 5 Performing Knives
10/15 DIVIDEND INCOME UPDATE : September 2017
Financials ($)
Sales 2017 25 836 M
EBIT 2017 16 052 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,64%
P/E ratio 2017 10,02
P/E ratio 2018 11,79
EV / Sales 2017 4,54x
EV / Sales 2018 5,01x
Capitalization 105 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,2 $
Spread / Average Target 4,9%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.65%104 788
REGENERON PHARMACEUTICALS20.67%47 421
VERTEX PHARMACEUTICALS107.56%39 091
ACTELION23.24%29 925
GENMAB22.08%13 010
EXELIXIS, INC.66.06%8 318